The involvement of DNDi will not end with drug registration or WHO recommendation. DNDi will take on the responsibility of ensuring that the new therapies it develops become useful treatments. Through interaction with pharmaceutical firms, international organisations, national disease control programmes, NGOs, and governments, DNDi will build a network with appropriate partners who can manufacture and distribute treatments (at affordable prices), ensure proper treatment utilisation and pharmacovigilance, and provide access to treatments. Distribution scenarios will vary depending on the disease, drugs, relevant countries, and degree of innovation: DNDi may tap into existing distribution networks or work with partners to create new channels (e.g., public or not-for-profit).